Pfizer "approvables"
Executive Summary
Company hopes to wrap up labeling negotiations with FDA for the antipsychotic Zeldox (ziprasidone) and the migraine therapy Relpax (eletriptan) before the end of the year, company says during Oct. 24 conference call